2023 World Conference on Lung Cancer (Posters)-P2.05. Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

P2.05. Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Pdf Summary

In the study presented at WCLC 2023, the pharmacokinetics of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) were evaluated. Cemiplimab is an immunotherapy drug that targets programmed cell death-ligand 1 (PD-L1) and has shown promising results in improving overall survival in patients with advanced NSCLC.<br /><br />The study included patients who received cemiplimab either as monotherapy or in combination with chemotherapy or with ipilimumab, another immunotherapy drug. Blood samples were collected at various time points to assess the pharmacokinetics of cemiplimab, including the maximum concentration (Cmax) and trough concentration (Ctrough). The concentrations of cemiplimab in serum were measured using a validated enzyme-linked immunosorbent assay.<br /><br />The results showed that the pharmacokinetics of cemiplimab were similar in patients receiving cemiplimab as monotherapy or in combination treatment, regardless of the histology (squamous or non-squamous) or PD-L1 expression. The Cmax and Ctrough values at steady-state were consistent across the different treatment regimens.<br /><br />The occurrence of treatment-emergent anti-drug antibodies (ADAs) against cemiplimab was low, with only a small percentage of patients showing immunogenicity. The presence of ADAs did not affect the concentrations of cemiplimab in serum.<br /><br />Overall, the study concluded that the pharmacokinetics of cemiplimab in patients with advanced NSCLC were consistent and unaffected by histology or PD-L1 expression. Furthermore, the occurrence of ADAs against cemiplimab was minimal and did not impact the pharmacokinetics of the drug.<br /><br />This study provides important insights into the use of cemiplimab in the treatment of advanced NSCLC and highlights its favorable pharmacokinetic profile.

Asset Subtitle

Petra Rietschel

Meta Tag

Speaker Petra Rietschel

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

WCLC 2023

pharmacokinetics

cemiplimab

non-small cell lung cancer

NSCLC

immunotherapy

PD-L1

overall survival

chemotherapy

ipilimumab